Ovoca Bio (LSE:OVB) Pre-Tax Income : £-3.41 Mil (TTM As of Jun. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Ovoca Bio Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Ovoca Bio's pretax income for the six months ended in Jun. 2024 was £-1.05 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2024 was £-3.41 Mil. Ovoca Bio's pretax margin was %.

Ovoca Bio Pre-Tax Income Historical Data

The historical data trend for Ovoca Bio's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovoca Bio Pre-Tax Income Chart

Ovoca Bio Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-1.61

-2.10

-4.46

-4.88

-4.40

Ovoca Bio Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Pre-Tax Income	Get a 7-Day Free Trial															-4.85	0.04	-2.04	-2.35	-1.05

Competitive Comparison of Ovoca Bio's Pre-Tax Income

For the Biotechnology subindustry, Ovoca Bio's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ovoca Bio's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovoca Bio's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Ovoca Bio's Pre-Tax Income falls into.

Ovoca Bio Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Ovoca Bio's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-1.608	+	0	+	-0.004	+	0	+	-2.785
	=	-4.40

Ovoca Bio's Pretax Income for the quarter that ended in Jun. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-1.05	+	0	+	-0.003	+	0	+	0
	=	-1.05

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-3.41 Mil.

Ovoca Bio (LSE:OVB) Pre-Tax Income Explanation

Ovoca Bio's Pretax Margin for the quarter that ended in Jun. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-1.053	/	0
	=	%

Ovoca Bio Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Ovoca Bio's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Ovoca Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovoca Bio PLC (LSE:OVB) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

OVXA:Ireland OVB.GB:UK OVXA:Germany

Address

17 Pembroke Street Upper, Dublin, IRL, D02 AT22

Website

https://www.ovocabio.com

Ovoca Bio PLC is a life science investment company. The company is engaged in investing in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. The group has two business segments, bio-pharmaceutical and investment, which are operated principally in Russian Federation and investment activities operated from Bermuda, and with administrative activities in the Republic of Ireland. Its product candidate includes IVIX - Libicore - a novel synthetic peptide, administrated through a nasal spray.